Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Immunol.

Sec. T Cell Biology

Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1655212

Distinct Arnica montana L. Extracts Modulate Human T Cell Activation in Different Ways via Differential Inhibition of NFκB and NFAT Pathways

Provisionally accepted
  • 1Institute of Immunology, Section Molecular Immunology, UniversitatsKlinikum Heidelberg, Heidelberg, Germany
  • 2Institute of Pharmacy and Molecular Biotechnology, Universitat Heidelberg, Heidelberg, Germany
  • 3Next Generation Sequencing Core Facility, Medical Faculty Mannheim, Universitat Heidelberg, Heidelberg, Germany
  • 4Institute of Experimental and Clinical Pharmacology, Toxicology and Pharmacology of Natural Products, Universitat Ulm, Ulm, Germany

The final, formatted version of the article will be published soon.

Arnica montana L. (Arnica) has a long history of use in treating inflammation and soft tissue injury, yet its immunomodulatory mechanisms remain largely unexplored. In this study, we investigated the effects of distinct Arnica extracts - derived from different plant parts (root or whole plant) and manufacturing processes - on primary human T cells. We also compared their effects with those of the pure compounds helenalin and thymol. All extracts inhibited T cell activation and proliferation. This could be traced back to reduced IL-2 responsiveness due to decreased CD25 (IL-2Ra chain) expression, accompanied by reduced IL-2 production. Transcriptomic analysis (nCounter) and gene set enrichment revealed that the extracts target key T cell receptor (TCR) signaling pathways. Mechanistically, the hydroethanolic root extract selectively inhibited NFκB DNA binding, while the aqueous fermented extract predominantly suppressed NFAT-dependent gene expression. The hydroethanolic whole plant extract exerted a moderate effect on both pathways. These findings identify Arnica extracts as promising modulators of human TCR signaling and support their potential in regulating T cell-driven inflammatory responses, with implications for muscle healing and chronic inflammatory diseases.

Keywords: Arnica montana L. extracts, primary human T cells (PBTs), Immunomodulation, NFκB, NFAT, Thymol, Helenalin

Received: 27 Jun 2025; Accepted: 29 Aug 2025.

Copyright: © 2025 Berschneider, Wetterauer, Sticht, Orlik, Jahraus, Kirchgeßner, Zuieva, Wölfl, Lairikyengbam, Beier, Wabnitz, Wetterauer, Schmiech and Samstag. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Yvonne Samstag, Institute of Immunology, Section Molecular Immunology, UniversitatsKlinikum Heidelberg, Heidelberg, Germany

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.